Forecast: (ALLO) for today October 27 & Weekly Forecast from 22 October to 28 October
Updated: October 27, 2023
Brief information about Allogene Therapeutics, Inc.
Closing price of the last trading day: $2.64
Last trading day: 10/26/2023
Analyst forecast price: $27.5
52-week high/low: $27.86 / $6.43
Shares of Allogene Therapeutics, Inc. are traded on the stock exchange under the ticker ALLO, marking their space in the competitive "Healthcare" sector. For stakeholders, tracking the dynamic price movement of ALLO is crucial for making informed investment decisions. In a market influenced by myriad factors, predicting the trajectory of these shares becomes both a challenge and a necessity. Predictive analytics and data-driven insights play a pivotal role in forecasting the performance of ALLO. The investors seeking up-to-date and accurate forecasts for Allogene Therapeutics, Inc. shares can turn to resources like Allforecast.com. The website stands out as a reliable tool offering real-time predictions, ensuring that investors are equipped with current and anticipated stock trends. On Allforecast.com, users gain access to a comprehensive analysis and predictions specifically tailored for ALLO, spanning varied timeframes - from the next day's anticipations to weekly, monthly, and yearly forecasts. The platform’s real-time updating mechanism ensures that the forecasted data aligns with the ongoing market trends and economic shifts, offering users actionable insights to optimize their investment strategies. The forecasts integrate a mix of qualitative and quantitative analyses, sector-specific trends within "Healthcare", and broader market dynamics to present a holistic view of ALLO's expected performance. By leveraging such precise and timely data, investors can strategize their moves, balancing risks and opportunities associated with Allogene Therapeutics, Inc.'s stocks. Navigating through the unpredictable terrains of the stock market requires actionable insights and timely data. Allforecast.com serves as a companion for investors eyeing ALLO, offering them a blend of accuracy and timeliness in predicting stock movements, aiding in informed and strategic investment choices.
Main Headquarters: Situated at 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, US, this location serves as the primary hub for all corporate activities.
Allogene Therapeutics's Current Market Value: As of our last update, it's pegged at $1 863 928 000, indicating its standing in the financial landscape.
Shares Overview: Currently, 143 600 000 shares of Allogene Therapeutics are actively traded and held by the public.
Last year's EBITDA (Earnings Before Interest, Taxes, and Depreciation) for Allogene Therapeutics stood at -290 355 008$. This figure provides insights into the company's operational profitability. On the other hand, a negative EBITDA hints at Allogene Therapeutics's current challenges in achieving profitability.
In addition to fundamental factors, stocks are influenced by many other factors. For example, it is worth monitoring all global forecasts for Allogene Therapeutics shares. Our service will help you with this, in which we collect all forecasts and build one consensus forecast from them.
Allogene Therapeutics stock forecast
When considering an investment in Allogene Therapeutics, prospective investors often seek insights on its long-term performance. Our platform consolidates the expert analyses and projections from renowned global analysts to offer a unified consensus forecast for 2023, 2024, 2025, 2026, and 2027.
With these forecasts at your disposal, you can address critical questions like:
What will be the price of one share of Allogene Therapeutics in the subsequent years including 2023, 2024, 2025, 2026, and 2027?
What consensus have the analysts reached regarding the future performance of Allogene Therapeutics stock?
Is Allogene Therapeutics stock a viable option for both short-term and long-term investment?
Is it prudent to sell or hold Allogene Therapeutics shares in 2023?
Is 2023 the opportune moment to buy Allogene Therapeutics stock, or is patience a more viable strategy?
What are the anticipated entry and exit points for investing in Allogene Therapeutics stock, according to expert forecasts?
It’s pivotal to remember that these forecasts are to be utilized as informational resources and not definitive investment advice. The final investment decision rests solely upon the investor, contingent on their risk tolerance, investment goals, and thorough analysis of Allogene Therapeutics.
Insight into Our Forecasting Process
Our forecasting methodology encompasses the aggregation of public and expert data on Allogene Therapeutics, coupled with a sophisticated algorithm that calculates a weighted average forecast while eliminating outliers. This ensures that our audience receives a refined and realistic projection of Allogene Therapeutics stock’s future performance.
Allogene Therapeutics Daily Share Price Forecast for One Month
Our team has meticulously gathered and analyzed forecasts from a diverse pool of analysts to present a consolidated average daily forecast for Allogene Therapeutics shares over the upcoming month. It’s essential to bear in mind that short-term predictions can often be subject to significant volatility, influenced by a myriad of dynamic, real-time market factors.
As you scroll, you’ll discover a detailed graph illustrating the consensus forecast for Allogene Therapeutics stocks over the next 30 days. The gray spectrum of the chart delineates the historical trajectory of the stock’s price, while the turquoise spectrum provides a visual representation of the anticipated price, inclusive of potential fluctuation ranges, offering insights into prospective market trends and stock behaviors.
In the dynamic world of stock trading, analysts and investors closely observe the projected highs and lows of Allogene Therapeutics shares. Our integrated forecast predicts a peak price of $2.96 in the forthcoming 30 days, indicating the zenith of the stock's potential performance. An encouraging revelation, denoting an upside potential of 12% from the current standing.
On the flip side, the stock might plummet to a minimum of $2.14 within the same period. A decline of 23.63% signals caution, nudging investors towards a more conservative stance.
Consequently, a fluctuation corridor emerges, with the stock’s resistance at $2.96 and support at $2.14, indicating the oscillating nature of Allogene Therapeutics’s stock over the one-month spectrum. These oscillations, while providing trading opportunities, should be navigated with adept knowledge and strategic foresight.
So, what’s the trajectory of Allogene Therapeutics amidst these projections? The nuances of stock trading and investment are encapsulated in the constant ebb and flow of the market, influenced by intrinsic and extrinsic factors. Hence, a comprehensive, nuanced understanding of market dynamics, coupled with real-time analytics, emerges as the cornerstone for maximizing ROI and mitigating risks.
The evolution of Allogene Therapeutics’s stock is akin to a narrative unfolding, shaped by myriad factors including market trends, economic indicators, and investor sentiment. Each fluctuation is a chapter of this narrative, offering insights, challenges, and opportunities to the discerning investor.
Evaluating the resilience of the support level is crucial in gauging the future trajectory of Allogene Therapeutics shares. The anticipation is that the price will hover near the support level for 1 days. The stability of Allogene Therapeutics at this level is relatively assured, signaling a low risk of a downward shift.
It’s imperative to remember the innate unpredictability of the stock market. The actual future value of Allogene Therapeutics shares is subject to variables beyond predictive analytics. Nonetheless, investors can expect the stock to oscillate within the defined optimistic and pessimistic target price brackets, offering both challenges and opportunities for strategic trading and investment.
Allogene Therapeutics Stock Forecast 29 Oct.
Allogene Therapeutics Stock Forecast 30 Oct.
Allogene Therapeutics Stock Forecast 31 Oct.
Allogene Therapeutics Stock Forecast 01 Nov.
Allogene Therapeutics Stock Forecast 02 Nov.
Allogene Therapeutics Stock Forecast 03 Nov.
Allogene Therapeutics Stock Forecast 04 Nov.
Allogene Therapeutics Stock Forecast 05 Nov.
Allogene Therapeutics Stock Forecast 07 Nov.
Allogene Therapeutics Stock Forecast 08 Nov.
Allogene Therapeutics Stock Forecast 09 Nov.
Allogene Therapeutics Stock Forecast 10 Nov.
Allogene Therapeutics Stock Forecast 11 Nov.
Allogene Therapeutics Stock Forecast 12 Nov.
Allogene Therapeutics Stock Forecast 13 Nov.
Allogene Therapeutics Stock Forecast 14 Nov.
Allogene Therapeutics Stock Forecast 15 Nov.
Allogene Therapeutics Stock Forecast 16 Nov.
Allogene Therapeutics Stock Forecast 17 Nov.
Allogene Therapeutics monthly stock forecast for 2023, 2024, 2025, 2026, 2027.
Diving into a more comprehensive insight, the monthly consensus forecast is an instrumental resource for investors eyeing Allogene Therapeutics's performance metrics. These projections are meticulously curated, leveraging insights from renowned global analysts and offering a panoramic view of the anticipated stock behaviour for the current year and beyond.
In the mid-term analysis, forecasting accuracy enhances, attributed to the diminished influence of transient market fluctuations. For this year, the zenith of Allogene Therapeutics share’s value is anticipated to touch $3.51, offering a robust metric for investment strategies, sans the extremes of varied agency forecasts.
On the contrary, the nadir projections settle at $3.05, delineating the lower threshold and offering a holistic perspective on the risk and return landscape.
Progressing further, we have extrapolated these analytical insights to generate consensus forecasts for subsequent years. The synthesized data, presented in intuitive tabular formats, offers investors, analysts, and enthusiasts a streamlined view into the future of Allogene Therapeutics stocks.
Anticipated Trends: Allogene Therapeutics (ALLO) Monthly Stock Trajectory for 2024
Allogene Therapeutics (ALLO) Monthly Stock Prediction for 2025
Allogene Therapeutics (ALLO) Monthly Stock Prediction for 2026
Allogene Therapeutics (ALLO) Monthly Stock Prediction for 2027
Stocks from the same sector (Healthcare)
All submitted consensus forecasts are exposed to get acquainted with the algorithm for collecting forecasts and bringing them to a single whole. The portal allforecast.com is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.